

An overview of treatment approaches for chronic pain management

Hylands-White, Nicholas; Duarte, Rui; Raphael, Jon

DOI:

[10.1007/s00296-016-3481-8](https://doi.org/10.1007/s00296-016-3481-8)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Hylands-White, N, Duarte, R & Raphael, J 2016, 'An overview of treatment approaches for chronic pain management', *Rheumatology International*. <https://doi.org/10.1007/s00296-016-3481-8>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

The final publication is available at Springer via <http://dx.doi.org/10.1007/s00296-016-3481-8>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

An overview of treatment approaches for chronic pain management

Nicholas Hylands-White, MRes ¹ Rui V Duarte, PhD ² Jon H Raphael, MD ^{1,3}

¹ Faculty of Health, Birmingham City University, Birmingham, UK

² Institute of Applied Health Research, University of Birmingham, Birmingham, UK

³ Department of Pain Management, Russells Hall Hospital, Dudley, UK

Address for correspondence: Nicholas Hylands-White, 178 Warley Road, Great Warley, Brentwood, Essex CM13 3AE, UK. Email nicholas.hylands-white@bcu.ac.uk

Conflicts of interest statement: The authors declare that they have no conflicts of interest.

Accepted for publication

Abstract

Pain which persists after healing is expected to have taken place, or which exists in the absence of tissue damage, is termed chronic pain. By definition chronic pain cannot be treated and cured in the conventional biomedical sense; rather the patient who is suffering from the pain must be given the tools with which their long-term pain can be managed to an acceptable level. This article will provide an overview of treatment approaches available for the management of persistent non-malignant pain. As well as attempting to provide relief from the physical aspects of pain through the judicious use of analgesics, interventions, stimulations, and irritations, it is important to pay equal attention to the psychosocial complaints which almost always accompany long term pain. The pain clinic offers a biopsychosocial approach to treatment with the multidisciplinary pain management programme; encouraging patients to take control of their pain problem and lead a fulfilling life in spite of the pain.

Keywords: chronic pain, pain management, biopsychosocial, psychology

Accepted for publication

Introduction

Pain is a common symptom of numerous medical problems, which usually indicates the occurrence of tissue damage. Whilst pain is unpleasant, it is also a useful mechanism with which to promote healing – forcing the sufferer to rest the affected area and seek out medical assistance. Pain associated with tissue damage, inflammation, or a disease process that is of relatively brief duration (days or weeks), is usually referred to as acute pain. When pain persists for extended periods of time – either as an accompaniment to a disease process, or following the usual amount of time expected for an injury to heal – it is referred to as ‘chronic pain’ [1]. The International Association for the Study of Pain (IASP) have defined chronic pain as that which lasts for longer than three months [2]. The pain persists long after it can serve any useful function and is no longer just a symptom of injury or disease but a medical problem in its own right [3]. ‘Chronic pain’ describes a syndrome characterised by persistent physical pain, disability, emotional disturbance, and social withdrawal symptoms existing together and influencing one another in what Bandura [4] termed ‘reciprocal determinism’. The source of the physical pain may be known or unknown: regardless, the sufferer of chronic pain will undergo a number of biological, psychological, and social upheavals over the course of their illness. In order to explain such a complex syndrome as chronic pain, we must not become fixated on finding biomedical causes, but also consider the roles of the psychological and social dimensions [5]. In what Jacobson and Mariano [6] have called a ‘biopsychosocial systems model’, people are viewed as living systems with multiple levels of analysis ranging from the cellular to the social. From this perspective, all three (bio, psycho, and social) dimensions of the model are given equal importance in their influence on personal experience.

Following this biopsychosocial approach, we may expect to find that treatments for chronic pain are a mix of medical, physical, and psychological components. Such treatments do exist in the context of a pain clinic, where several disciplines of pain treatment are delivered simultaneously. However, patients are seldom referred to multidisciplinary treatment as soon as their pain becomes chronic [7]. More often, the patient is treated as though they are suffering from an extended period of acute pain, which means that numerous medications and interventions are tried and tested, with the goal of reducing the pain to an acceptable level. This review will describe the range of treatments which exist for the management of pain, in the approximate order by which they are applied to the sufferer of chronic pain.

Methods

A narrative review of studies investigating treatment approaches for the management of chronic pain was carried out according to published guidance on narrative reviews [8]. We searched MEDLINE and EMBASE up to November 2nd, 2015. A combination of MESH and free text terms was employed including pain, chronic pain, analgesics, opioids, neuromodulation. Studies were selected for inclusion if examining treatments for the management of chronic pain. The search was restricted to articles published in English. A hand-search of the reference lists of studies meeting the inclusion criteria was also performed.

Analgesic Medication for Pain

Conventional oral analgesics are always the first treatment given; they can be a fast, cheap, and relatively safe solution to the problem of pain. There are also a large number to choose from. In treating a case of pain the physician usually follows the steps on the World Health Organisation (WHO) analgesic ladder (Figure 1) [9]. Initially developed for the treatment of cancer pain, but applicable to most pain conditions, the ladder suggests that analgesic medications should be given orally with increasing dose and potency until pain relief has been achieved. It is a simple and inexpensive approach that produces pain relief in 80-90% of cancer patients [10]. When applied to chronic non-cancer pain, patients rarely achieve long-term pain relief as side-effects tend to limit maximum dosage, and mean pain relief from opioids has been reported to be around 30% [11].

Non-Steroidal Anti-Inflammatory Drugs

The first step of the ladder consists of non-opioid analgesics, such as paracetamol and the non-steroidal anti-inflammatory drugs (NSAIDs). These act to reduce inflammation and provide pain relief, reducing the production of inflammatory chemicals by inhibition of the cyclooxygenase enzymes COX-1 and COX-2. These enzymes catalyse the production of two types of eicosanoids: prostaglandins (PGs), which cause vasodilatation, increase vascular permeability, sensitise nociceptors, and inhibit gastric acid secretion and platelet aggregation; and also thromboxanes (TXs) which cause platelet aggregation and vasoconstriction. COX-1 is constituent to most tissues of the body, producing PGs and TXs for tasks such as gastrointestinal (GI) protection, maintenance of renal blood flow, and platelet aggregation [12]. By contrast COX-2 is mainly induced in inflammatory cells in response to damage, and is therefore chiefly responsible for the effects of inflammation – including pain [13]. Non-selective COX inhibitors act on both COX-1 and COX-2 and include aspirin, ibuprofen, and naproxen. The side-effects of these drugs are mainly due to their inhibition of COX-1. GI ulcers and their complications occur in 2% to 4% of patients on high doses [14] and for this reason they are often administered alongside a proton-pump inhibitor to protect the stomach lining from acid secretion. Selective inhibitors of the COX-2 enzyme (coxibs), including celecoxib and etoricoxib, were developed in the early 1990s and subsequent studies showed that pain relief could be achieved without the gastrointestinal and renal side effects of the traditional NSAIDs [14–16]. However, once the coxibs were in widespread use a number of controlled trials revealed a strong association with increased risk of serious thrombotic cardiovascular (CV) events [17–21] and many were withdrawn. Coxibs have since been shown to suppress COX-2 mediated production of platelet PG-I₂ (an inhibitor of platelet aggregation) but not COX-1 mediated TX-A₂ (a promoter of platelet aggregation), thus promoting a prothrombotic vascular state [22–24]. By contrast, the non-selective NSAIDs somewhat suppress platelet TX-A₂ production through COX-1 inhibition; however they do vary in degree and duration of platelet COX-1 inhibition [25, 26] and have also been linked with an increased risk of thrombotic events [27]. More recent meta-analyses of long-term use of high dose NSAIDs have found that all increase the risk of coronary heart disease (CHD) and thrombotic CV events to some extent [28–30] (with the exception of naproxen, which has a long lasting suppressive effect on TX-A₂ production [25, 26]). The European Medicines Agency's Committee for Medicinal Products for Human use (CHMP) guidelines contraindicate the use of coxibs in patients with CHD or stroke, and recommend caution when used for patients with risk factors for CHD [31]. The CHMP also concluded that the benefit-risk balance for non-selective NSAIDs is favourable, but emphasise judicious use based on individual patient risk factors [32]. If high doses of NSAIDs are required to control pain, it is sensible to make use of alternative

treatments in the first instance rather than expose those patients to the cardiac, GI, and renal risk of long-term use.

Weak and Strong Opioids

The second step of the ladder adds weak opioids, codeine and dihydrocodeine. Opioid drugs mimic the effects of naturally occurring pain reducing chemicals (endorphins) which activate opioid receptors in the central nervous system that attenuate transmission of nociceptive signals. Long-term use (>180 days) of codeine carries an increased risk of CV events in older patients [33]. The third step calls for strong opioids, which are more potent but also have more severe side effects than weak opioids. Opioids suppress nerve activity via activation of G-protein coupled opioid receptors which promote K^+ (causing hyperpolarisation) and inhibit Ca^{2+} (reducing transmitter release) entry into the nerve cell [12]. Endogenous opioid networks are involved in the regulation of many physiological functions as well as pain; therefore side effects always accompany administration of opioid medication. Respiratory depression occurs at therapeutic doses and can be fatal, so patients are always started at a low dosage which can be increased as tolerance develops. Also nausea, constipation, cognitive impairment, sedation and various hormonal effects are concerns with chronic opioid use [11]. The nervous system rapidly develops tolerance to the effects of opioids [34], including the analgesic effect, which means that dosage needs to be increased over time to achieve pain relief. Unlike the weak opioids, the effects of the morphine-like drugs increase as a function of dosage, therefore dose can be increased (almost indefinitely) to combat tolerance and rising levels of pain. In practice, patients tend to reach their own maximum dosage at which they can no longer accept any further increase in side effects. Recent reviews have suggested opioids for chronic pain have good short-term efficacy in musculoskeletal and neuropathic pain conditions [11], but there is less evidence for long-term efficacy beyond six months [35], which may be due to the effects of opioid tolerance and opioid induced pain sensitivity [36]. A cautious approach to dose escalation and the discontinuation of opioids if treatment goals are not met has been recommended [35, 36]. Despite widespread use of opioids in the treatment of fibromyalgia [37], there is no good quality evidence of their efficacy [38]. Opioid receptor function has been shown to be compromised in patients suffering with fibromyalgia [39], which may explain the poor response to exogenous opioids in this population. Recent work has suggested that chronic opioid use may actually worsen fibromyalgia symptoms [40], and Canadian [41] and German [42] guidelines strongly discourage their use in this condition.

Topical analgesics

The lipophilic opioids, fentanyl and buprenorphine, are suited for transdermal route of administration as they are readily absorbed through the skin, entering the blood rapidly. The use of fentanyl patches is associated with fewer side-effects than sustained-release oral morphine, including constipation and sedation, whilst providing adequate pain relief in non-cancer pain patients [43]. Buprenorphine also carries fewer side effects compared to oral morphine, and has been shown to be effective in a variety of pain conditions including osteoarthritis, low back pain, and neuropathic pain [44]. Lidocaine (an amide anaesthetic that inhibits nerve depolarisation through sodium channel blockade) can also be applied as a cream or patch to provide localised pain relief, and has been recommended for use in relief of peripheral neuropathic pain [45]. It is poorly absorbed across the skin so side effects are rare [46] and despite

individual studies reporting efficacy in the relief of neuropathic pain a recent Cochrane review found no good quality evidence to support its use [47].




Figure 1. The WHO analgesic ladder (adapted from [9], p.94)

Adjuvants

The adjuvant medications referred to by the 1986 WHO analgesic ladder are ‘*additional drugs... to calm fear and anxiety*’ [9] that can be added at any step of the ladder. It should be noted that these are not the same as ‘adjuvant analgesics’, which are drugs with indications other than pain that may be analgesic in certain conditions. The terms ‘adjuvant’ and ‘adjuvant analgesic’ are conflated in pain literature; perhaps because anxiolytic drugs such as antidepressants and antiepileptics have since been found to be effective pain relievers in specific circumstances; or perhaps due to careless use of the terms which are admittedly very similar and easily confused. The adjuvants in the sense of the WHO ladder include anxiolytics to reduce pain related anxiety; hypnotics to tackle pain related insomnia; and muscle relaxants to relieve painful muscle spasm. These drugs may be added at any time depending on the individual needs of the patient.

Adjuvant Analgesics

Sometimes known as unconventional analgesics; drugs that were initially developed as antidepressants and as antiepileptics (anticonvulsants) have been found to exhibit analgesic properties when administered to patients with pain. The ‘+/- adjuvant’ label on the WHO ladder has come to refer to these types of drugs, although it is not clear if that is what it originally meant.

In chronic pain conditions where opioid medication is often ineffective such as neuropathic pain [12] and fibromyalgia [38], some types of antidepressant drugs have been found to exhibit analgesic properties which are unrelated to their antidepressant effects. Most effective are the tricyclic antidepressants (TCAs) and serotonin and noradrenaline reuptake inhibitors (SNRIs), which both act to prevent reuptake of

noradrenaline and serotonin in the brain and spinal cord. They are thought to provide analgesia by enhancing endogenous pain control and increasing the activity of the descending inhibitory pathway, however this remains unclear [48]. Selective serotonin reuptake inhibitors (SSRIs) provide little pain relief [45, 49, 50]. Antidepressants are often prescribed to chronic pain patients to treat comorbid depression and sleep problems, as well as for pain relief. After anti-inflammatory drugs and opioids, antidepressants are the most widely used drugs for the treatment of pain [51].

Antiepileptic drugs can also provide analgesia in fibromyalgia and neuropathic pain patients. Gabapentin and pregabalin act to reduce release of excitatory neurotransmitters (including glutamate, noradrenaline, substance P, and calcitonin gene-related peptide [52]) from nerve terminals by inhibiting the alpha-2-delta subunit of the voltage-gated calcium channel [53]. Carbamazepine is effective for trigeminal neuralgia, but not other conditions [12]. Good quality evidence demonstrates that pregabalin an effective analgesic in fibromyalgia, perhaps acting to dampen central sensitisation, but this is not clear [54].

Interventional Pain Management

The WHO pain treatment guidelines take in most of the available analgesics, however invasive procedures are not included. These include nerve block injections, denervation surgery, implantable drug delivery systems, and nerve stimulators. Invasive procedures are often risky and expensive, so they are usually reserved for cases that do not respond to oral and systemic analgesics. As these treatments have become more widely available, some authors have suggested that they be included in the pain ladder as a fourth step, coming after the strong opioids (e.g. [55, 56]). This would bring the 1986 pain ladder up to date by including more recent treatments. However, it could be argued that adding this extra step is not such a good idea: the 3-step ladder has persisted because it is simple and effective; it works because increasing the dose of a medication usually results in a reduction in pain. Adding invasive treatments as a fourth step might appear to condone the automatic use of these treatments. In cases where these treatments are unsuitable or ineffective, to use them anyway because they are the next option would be irresponsible, wasteful, and potentially harmful to patients. Leaving them out of the ladder reinforces the fact that these treatments are only suitable for use in a minority of patients, and then only after careful consideration.

Nerve block injections of steroid plus local anaesthetic into the epidural space are common for back pain, however clinical effectiveness remains debateable. In 1995 Watts and Silagy [57] published a meta-analysis concluding that epidural steroid injection was significantly more effective than placebo in providing $\geq 75\%$ pain relief for up to six weeks. The number needed to treat (NNT) reveals that the level of pain relief was only achieved in 1 out of every 7 patients. McQuay and Moore [58] looked at the same data in 1998, and calculated the NNT for a more reasonable $\geq 50\%$ pain relief in the short-term to be 1 in 3. Injections into facet joints of the spine are commonly used for relief of radicular pain. Evidence for efficacy is limited for cervical injections and moderate for lumbar level injections [59]. The most recent Cochrane review of this procedure concluded that there was no strong evidence for or against the use of injection therapy, but did not rule out the possibility that specific subgroups of patients may respond to a specific type of injection [60].

Surgical procedures for the treatment of chronic pain have traditionally involved the destruction of peripheral and central nerve cells in an attempt to stop 'pain signals' reaching the brain. Surgery is invasive, irreversible, carries a high-risk of complications, and is not always effective, therefore it is often saved until all other pharmacological and physiological treatments have been tried without success. The supposed benefits of surgery rest on the principles of the now defunct specificity theory: surgery can interrupt the 'pain signals' from reaching the 'pain centre' in the brain. This type of surgery rarely puts an end to the pain, and if successful seldom offer more than temporary relief. Despite this negative assessment, a handful of successful cases are touted as good reason to perform surgery in those who are desperate enough to believe that whatever the outcome, it is preferable to their current state of suffering. A notable exception to the high-risk/low-success surgeries is radiofrequency denervation of facet joint sensory nerves, which is moderately successful for the treatment of back and neck pain caused by nerve irritation at the facet joints of the spine. There is moderately good evidence that it provides better pain relief than sham intervention, with approximately 50% of patients reporting at least 50% pain reduction [61]. Pain typically returns 6-12 months later; however the procedure can be repeated with similar efficacy and there are no reported side effects [62].

In contrast to these destructive procedures, pain can also be treated by surgical implantation of therapeutic devices into the body. Intrathecal drug delivery systems (IDDS), first implanted in 1981 [63], use a pump to deliver small quantities of opioid medication directly into the cerebrospinal fluid via a catheter inserted into the intrathecal space. The drug is delivered at the site of action, meaning much lower doses are needed to achieve analgesia compared with oral opioids (ratio of dose is approximately 300:1; [64]). Therefore only a small amount of drug enters the circulatory system and becomes absorbed by the rest of the body - resulting in fewer side effects and any increase in dosage will give greater analgesia relative to an increase in side effects, compared to oral opioids [65]. The evidence on IDDS for chronic non-cancer pain is currently limited to case series and a small randomised controlled trial (RCT) which supports the efficacy of intrathecal opioids in long term patients [66]. Taking also into account its invasive nature, high initial cost and risk of complications, this technology is not regularly used.

Spinal Cord Stimulation

An alternative to interrupting nerve transmission with drugs is to use electrical stimulation delivered by electrodes placed next to the spinal nerves in the dorsal epidural space. Developed as a clinical application of gate control theory [67], spinal cord stimulation (SCS) delivers an electric field to the dorsal horn and dorsal column axons, which inhibits activity in the spinothalamic tract [68]. The patient experiences paraesthesia over the area served by the SCS affected nerves, which is matched to the painful area by altering the position and settings of the electrodes during implantation. The stimulator unit is implanted subcutaneously and can be reprogrammed remotely by the physician. Recent developed rechargeable SCS devices allow the patient to recharge the unit and also increase the longevity of the device. Due to high initial cost and risk of complications, SCS is usually reserved for patients who do not respond to other less invasive forms of treatment. SCS is currently recommended by NICE in the UK for use in chronic pain of neuropathic origin continuing over six months despite standard treatments [69]. Treatment effects tend to diminish over time: in one study 67% of patients reported $\geq 50\%$ reduction in pain relief lasting more than six months [70], another study 47% had $\geq 50\%$ pain relief after 24 months [71]. For those patients in whom SCS is beneficial, opioid medication can be reduced, there is a significant improvement in quality of life, and side effects are rare. A recent study [72] suggested that

long term efficacy of SCS is related to improvements in psychological factors including depression and autonomous coping (control over pain, ability to reduce pain, and catastrophising), although the mechanism remains unclear. Despite high initial cost and uncertainty of a successful outcome, SCS can be an effective intervention for many patients, it is reversible in the event of complications, and the treatment is performed in over 14,000 patients each year worldwide [73].

SCS has also found success in treatment of ischaemic pain arising from peripheral arterial occlusive disease (PAOD), and in the alleviation of angina pain. Extensive studies (reviewed in [74]) have revealed that SCS acts to reduce peripheral ischaemic pain by promoting the release of neuropeptides and reducing the activity of α -1 adrenergic receptors, both of which result in vasodilatation; which combines with the suppressive effect on nociceptive transmission. SCS has been shown to promote healing of ulcers [75] and reduce need for amputation in lower limb PAOD [76]. The mechanisms by which SCS acts on the heart to relieve the pain of angina have also been studied. There is no evidence that SCS works to increase coronary blood flow [35, 36], but may act to redistribute blood flow [79]; and it has been suggested that the benefit of SCS to cardiac function comes from regulation of the intrinsic cardiac nervous system [73], acting to suppress arrhythmias and attenuate ST segment elevations [74]. Systematic reviews of RCTs using SCS in the treatment of refractory angina revealed significant improvements in exercise capacity and health related quality of life for those treated with SCS [39, 40]. SCS is not currently recommended by NICE for use in ischaemic pain conditions such as angina due to inadequate evidence [69]. To address these uncertainties, a pilot RCT compared the use of SCS to current usual care management for refractory angina [82]. A trend toward larger improvements in both primary and secondary outcomes in the SCS group was observed although the study was not formally powered to compare outcomes between the groups.

Deep Brain Stimulation (DBS)

Implantation of electrodes to stimulate brain structures involved in the transmission and regulation of nociceptive signals (the periventricular grey matter and lateral somatosensory thalamus) is a highly invasive and risky treatment method that has been in experimental use since the 1950s [83]. For these reasons DBS is only used in carefully selected patients who have not responded to all other forms of treatment, however in these few cases satisfactory and lasting pain relief has been achieved in over 50% of patients [84, 85]. DBS is approved for use in the UK for treatment of refractory chronic pain [86], in Europe for neuropathic pain [87], and is not currently approved in the USA [88].

Repetitive Transcranial Magnetic Stimulation (rTMS) and Transcranial Direct Current Stimulation (tDCS)

Non-invasive brain stimulation techniques rTMS and tDCS use equipment placed onto the scalp to induce activity in the underlying cortex via electromagnetic force (see [89] for review). Their use in pain is primarily investigational; however there is evidence for a reduction in pain when applied over the motor cortex for repeated sessions of 20 minutes or more in patients with fibromyalgia [90] and neuropathic pain [87]. Both techniques have a very few side-effects, which may include discomfort at the stimulation site and headache during stimulation, and are therefore worth trying first in patients who would otherwise undergo a surgical procedure [87].

Pain Relief by Counter-irritation

A well known phenomenon in traditional medicine, the ‘pain inhibiting pain effect’ [91] or counter-irritation [92] is the relief of pain by application of intense stimulation to the painful area or another area of the body. The mechanism of action by which pain relief is achieved depends upon the technique used.

Transcutaneous Electrical Nerve Stimulation (TENS) and Percutaneous Electrical Nerve Stimulation (PENS)

Electrical nerve stimulation via electrodes placed onto the skin (transcutaneous) or inserted into the skin (percutaneous) is used to treat a wide range of acute and chronic pain conditions, and is popular among doctors, nurses, and physiotherapists [93]. Although the use of peripheral stimulation (e.g. rubbing, vibration, heat, cold, and electrical) for pain relief has been known for thousands of years [94], an explanation for its effect was not offered until gate control theory (GCT) in 1965 [67]. Under GCT, peripheral stimulation activates large ($A\beta$) nerve fibres which activate spinal inhibitory neurons that attenuate small (C) fibre nociceptive activity and reduce pain. TENS has been demonstrated to inhibit nociception via this mechanism in animal and human studies [95]. Nash and colleagues [96] reported that if TENS was used for at least 30 minutes twice per day, 15% of patients achieved a 50% pain reduction after one month, rising to 51% of patients after 24 months. McQuay and colleagues [97] concluded that TENS may be useful for chronic pain but there is no useful evidence, likely due to the fact that none of the RCTs included in the meta-analysis used anywhere near the doses of TENS recommended by the Nash study [96]. Despite lack of evidence of effect, TENS is effective for some patients and remains widely used. Evidence for efficacy of PENS is also limited, however at least one RCT has demonstrated that PENS is significantly more effective than sham intervention for short term relief of chronic pain [98].

Topical Capsaicin

Capsaicin is the compound present in chilli peppers, and can be applied externally as a cream or patch. The application of capsaicin is painful itself, therefore it was originally believed to work by distracting the patient from their pain by replacing it with another pain i.e. counter-irritation [99]. It is now known that capsaicin binds to the transient receptor potential cation channel subfamily V member 1 (TRPV1) membrane receptor, causing depolarisation and the generation of action potentials, which are felt as burning, pricking or itching sensations [100]. After repeated applications or high concentrations of capsaicin, there is a loss of normal function of the nerve cell and a persistent desensitisation to noxious stimuli, termed ‘defunctionalisation’ [101]. Good quality evidence of the effectiveness of capsaicin has been difficult to gather, as the burning effect of capsaicin makes blinding almost impossible. Trials confirm that high concentration capsaicin (8%) is a more effective pain reliever than lower concentrations, if the patient can overcome the initial discomfort [102], and can reduce consumption of opioid medication [103]. As topical capsaicin is relatively safe, easy to use, and has the potential to benefit some patients, it is ‘worth a try’ in patients who are suffering long term pain, and accounted for over 224,000 prescriptions in the UK in 2013 [104].

Heat/Cold

Superficial application of heat or cold (thermotherapy and cryotherapy, respectively) may be effective in providing immediate, short-term relief from pain [105]. Superficial heat helps to relax muscles that are

tense or in spasm, and increase local circulation, thus reducing pain and stiffness [106]. Cryotherapy reduces muscular temperatures and acts to decrease local metabolism, inflammation, and pain [107]. The analgesic effect is thought to result from a decrease in nerve conduction speed and a reduction in muscle activity [108]. Heat and cold treatments are widely available, simple to use, cost effective, and patients will find out for themselves if they can benefit from them or not.

A Possible Mechanism for Counter-irritation

Experimental studies, in which brief noxious stimuli are applied to one area whilst another receives ongoing painful stimulation, shed light on a common mechanism that may subserve counter-irritation. A reduction in the activity of pain signalling neurons (in the spinal dorsal horn and trigeminal nuclei) when noxious stimuli are applied to a remote area of the body constitute a form of endogenous analgesia termed 'diffuse noxious inhibitory controls' (DNIC; [59, 60]). Although the phenomenon of DNIC has only been observed under experimental conditions, it may explain the beneficial effects of the above methods of counter-irritation which have been observed in patients.

Biopsychosocial Treatments

Up to this point, we have been discussing treatments which are essentially 'done to the patient', and thus fit into the biomedical model of pain treatment. The psychosocial health of the patient has been put to one side, perhaps with the expectation that the attenuation of pain will bring about an improvement in mental health and quality of life. However, chronic pain is as much a psychosocial problem as it is a physiological one: anxiety, depression, stress, anger, insomnia, suicide, loss of financial independence, disability, and family instability are closely associated with long-term pain. The neuromatrix theory [111] suggests that in the absence of overt physical damage, it is the psychological factors of emotion and cognition that contribute most to the experience of pain. In turn, these psychological factors are influenced by the social and cultural environment in which the patient is living, and perhaps also by side effects of pain reducing medications. The multiple aspects of the pain experience call for a complex form of treatment that can simultaneously address biological, psychological, and social issues. Such treatment draws on the knowledge of several healthcare disciplines including physicians, psychologists, specialist nurses, physiotherapists, and occupational therapists; combining to deliver what is known as multidisciplinary pain management. In a survey of chronic pain patients in 15 European countries and Israel, 23% reported they had been to see a pain management specialist [112]. In the UK, a patient will be referred by their general practitioner to the local pain clinic (of which there were 214 in 2010 [113]) for multidisciplinary treatment. On entering the pain clinic system the patient meets individually with each member of the team in order to discuss their situation and how treatment should proceed.

Physiotherapy

The goal of physiotherapy for chronic pain is to maximise and maintain the patients' functional ability, without contributing to any increase in pain. Passive modalities are less likely to be used, as they are believed to reinforce dependence on external factors when the patient should be encouraged to take responsibility for their own improvement [114]. Patients are taught that pain does not necessarily imply that tissue damage is taking place, and that avoiding activity can actually worsen pain in the long run

through deconditioning. The physiotherapist may also help to validate the patient's condition, explaining that results of physical examinations, magnetic resonance imaging (MRI) scans, and other diagnostic tests often correlate poorly with pain severity and should not be relied upon as a measure of disability. Physical treatment is based on a set of stretches and light aerobic exercises performed on a daily basis, to regain muscle strength and improve range of movement that can be performed without exacerbating pain. A review of exercise therapy for chronic low-back pain concluded that it is slightly effective at decreasing pain and improving function [115].

Occupational Therapy

Occupational therapy interventions focus on increasing physical capacities, mastery of self and environment through activities, and productive and satisfying performance of life tasks and roles [116]. Patients are taught early on that rest is not a good way to deal with chronic pain, and that the performance of a baseline level of daily activity is the key to recovery. The therapist works with the patient to determine the amount of activity that can be performed without exacerbating the pain. Patients' keep a 'pain diary' noting the types of activity, duration, and pain level they experience throughout the day; which can help the patient observe what they are doing to worsen their pain. Activities are planned in advance, including regular breaks for rest – a technique known as 'pacing'. Adaptive equipment may also be required for the patient to perform tasks, for example, a perching stool allows patients' to sit during tasks such as food preparation or washing up.

Pain Specialist Nursing

The nurse specialising in pain can advise patients on their medications, explaining the reasons why they have been prescribed, and suggesting the best time of day to take them to minimise the impact of side effects. Patients can be confused and worried when they are prescribed an antidepressant for their pain, which may lead to non-compliance; if patients understand why they are taking particular medications, they are more likely to take them [117].

Clinical Psychology

The clinical psychologist is concerned with the impact that the pain condition has on the mental health and wellbeing of the patient. Initial assessment involves psychological screening to ascertain how the pain has affected mood, sleep, appetite, motivation, daily activities, relationships, work, and finances. Patients' may be unsure why they are seeing a psychologist for pain treatment; it somehow implies that their pain is a psychological rather than a physical problem. The psychologist must take care to explain the role of non-physiological factors in the maintenance of pain symptoms and their responses to treatment [118]. Of vital importance to recovery are the ways in which the patient reacts to, and copes with physical pain and the emotional suffering that accompanies it. There are numerous approaches to psychological treatment: motivational interviewing, psychodynamic psychotherapy, operant therapy, cognitive-behavioural therapy, biofeedback, hypnosis, graded exposure, mindfulness based stress reduction, acceptance and commitment therapy, solution-focused brief therapy, and others. In a pain clinic setting, patients are often invited to attend a group therapy programme which combines elements of psychological treatment from various approaches with physiotherapy, occupational therapy, information on medication, pain physiology, sleep hygiene, local support groups, and relaxation techniques.

Patients may continue to meet regularly with team members to receive ongoing treatment and monitor progress, however it is likely that the patient will eventually be recommended to attend a series of group treatment sessions known as the pain management programme (PMP) of which there were 97 in the UK in 2013 [119], and approximately 150 in the USA in 2011 [120].

Multidisciplinary Pain Management Programmes

PMPs are based on the biopsychosocial model, in which behaviours are believed to reflect a combination of: physical events, the recognition and appraisal of these events, affective responses to these events, and environmental influences [121]. The programme addresses all of these components simultaneously. Typically, patients are treated in groups of 5-15, over a course of 8-12 sessions taking place once or twice a week on an outpatient basis. The group format normalises the experience of pain and maximises opportunities to draw on the experiences of group members; it is also cost effective ([122], p.8). Sessions last 3-4 hours and consist of physical, psychological, medical, and occupational themes. Each session will generally proceed using the same structure of five components, the contents of which change from session to session: exercise, education, skills training, relaxation, and homework. Pain management programmes tend to differ according to the psychological approach upon which they are based, and two of these approaches will be discussed now.

Cognitive-Behavioural Therapy (CBT)

Under the cognitive-behavioural approach, individuals are not seen merely as passive responders to their environment, but as active processors of information, basing their responses on their own personal version of reality – which is constantly being revised and updated through sensory, emotional, social, environmental, and cognitive factors [123]. Over the lifetime, individuals learn ways of interpreting these factors as they are added to their version of reality, some of which may be viewed as positive, and some negative. It is the negative, or maladaptive, ways of thinking, feeling, and behaving that are the targets of CBT. Patients are taught to become aware of the connections between thoughts, feelings, and behaviours – to recognise that negative thoughts and feelings about the pain are directly linked to maladaptive behaviours and exacerbation of symptoms [124]. Unrealistic or unhelpful thoughts about pain and pain catastrophising are identified and replaced with thoughts oriented towards adaptive behaviour and positive functioning, through cognitive restructuring. Pain symptoms themselves are reconceptualised during the therapy process, with patients learning that they can control their symptoms to an extent by employing the cognitive and behavioural skills acquired during therapy [125].

The success or failure of CBT relies on the patient entering into a collaborative effort with the therapy team; they must be willing to reveal personal thoughts and feelings, and be prepared to take responsibility for their own well being by making every effort to put the skills they have learned into practice on a daily basis. It is likely that patients will initially hold the view that their pain is a medical problem and should be treated as such – by medications, manipulations, and surgery. It is therefore vital that this view is challenged at the outset, that the therapist takes time to explain the rationale of CBT, and that the patient understands their role in the treatment process. However, the patient should not be given false hope by being told that if they unquestioningly do everything asked of them, their pain will be cured, rather the patient should be encouraged to approach the therapy with a sense of sceptical optimism. A number of

meta-analytic studies present convincing evidence that psychological therapies including CBT are more effective in bringing about improvements in coping and mental health than pharmaceutical treatment alone [126–130]. It should be noted that CBT does not usually bring about a reduction in pain *per se*; however this is not a goal of the treatment so it should not come as a surprise. In cases of refractory angina, a programme of education and self-management using an outpatient cognitive-behavioural programme has been successful in reducing angina symptoms. Patients attending the programme showed significant improvement on measures of angina frequency and stability, quality of life, anxiety and depression [131]; as well as a reduction in hospital visits, and a reduction in healthcare costs [132].

Acceptance and Commitment Therapy (ACT)

ACT is an approach to treatment designed around processes from the psychological flexibility model and based in operant theory and relational frame theory [133–137]. In contrast to CBT, thoughts, feelings, and behaviours are not seen as the problem which must be addressed – it is the *response* to these factors which is the target for change: it is the tendency to react in maladaptive ways and fight against the pain that causes suffering. The patient is encouraged to question whether their current courses of action are preventing them from, or helping them move towards, their life goals and values. The patient may be concerned with the eradication of pain in order to live a better life: the lack of pain is not the ultimate goal; it is a means to an end. In chronic pain this means can never be achieved, and ACT suggests abandoning that means as it really presents a barrier to moving towards the goal of a better life [134]. ACT provides techniques that the patient can use to deal with the thoughts of pain, to minimise focus on reducing pain or thought content, engage in a process of defusing and letting go, and move towards their values and goals [134, 138]. An important technique employed to foster acceptance, to help view the self as separate from thoughts and emotions, and to aid defusion and letting go of automatic thoughts is ‘mindfulness’. The essence of mindfulness is paying attention to the present moment without attaching meaning or judgmental language to thoughts that arise [139]. Seeing thoughts as transient events, separate from the self, cultivates psychological flexibility, allowing the patient to deal with difficult thoughts and feelings that might otherwise become barriers to pursuing their goals. ACT differs from CBT in the regard that it does not attempt to change thoughts and feelings: how a person has dealt with their problems in the past is not important. Patients can learn to use the skills taught in ACT to begin living a fulfilling life right away, without first ‘winning a war with [their] own history’ ([134], p.652). The use of ACT as a treatment approach for chronic pain problems has grown steadily over the past 15 years. During this time evidence has accumulated that supports the use of ACT as a good alternative to CBT, with similar effects on a range of treatment outcomes [140, 141].

Conclusion

Pain is a multidimensional problem that must be explained and treated using a combination of biological, psychological, and social approaches (Table 1). When it comes to the treatment of chronic pain, the biopsychosocial approach provides a wider scope of inquiry and intervention than a biomedical view, and shifts the focus of the treatment away from just physical pain relief towards strategies that increase functional ability and wellbeing in spite of the pain. Such treatments are crucial in ensuring that patients maintain a satisfactory quality of life and deal with the anxiety, depression, and social upheaval which accompany persistent physical pain.

Table 1. Treatment approaches for chronic pain management

Biomedical		Biopsychosocial	
Less Invasive	Topical Analgesic	Pharmaceutical	Physiotherapy
	Oral Analgesic		Occupational Therapy
	Adjuvant Analgesic		
	Nerve Block Injection		
More Invasive	Intrathecal DDS	Surgical	Specialist Nursing
	Nerve Section		Clinical Psychology
	Deep Brain Stim.	Electrical	Cognitive Behavioural Therapy
	Spinal Cord Stim.		
	Percutaneous ENS		
Less Invasive	Transcutaneous ENS		Acceptance and Commitment Therapy
	Repetitive TMS		
	Transcranial DCS		

Abbreviations used: DDS = Drug Delivery System; Stim. = Stimulation; ENS = Electrical Nerve Stimulation; TMS = Transcranial Magnetic Stimulation; DCS = Direct Current Stimulation

Funding statement: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Ethical approval: This article does not contain any studies with human participants or animals performed by any of the authors.

References:

1. Turk D, Melzack R (2011) The Measurement of Pain and the Assessment of People Experiencing Pain. In: Turk D, Melzack R (eds) *Handb. Pain Assess.*, 3rd ed. Guilford Press, NY, p 542
2. International Association for the Study of Pain (1986) Classification of Chronic Pain: Introduction. *Pain* 24:S3–S8. doi: 10.1016/0304-3959(86)90107-7
3. Melzack R, Wall PD (1996) *The Challenge of Pain*, upd. 2nd. Penguin, London
4. Bandura A (1978) The self system in reciprocal determinism. *Am Psychol* 33:344–358. doi: 10.1037/0003-066X.33.4.344
5. Engel G (1977) The need for a new medical model: a challenge for biomedicine. *Science* (80-) 196:129–136.
6. Jacobson L, Mariano A (2001) General considerations of chronic pain. In: Loeser J (ed) *Bonica's Manag. Pain*, 3rd ed. Lippincott, Williams & Wilkins, Philadelphia, PA, pp 241–254
7. Loeser J (1991) The role of chronic pain clinics in managing back pain. In: Frymoyer J (ed) *Adult Spine Princ. Pract.* Raven Press, New York, NY, pp 221–229
8. Gasparyan AY, Ayyvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: Considerations for authors, peer reviewers, and editors. *Rheumatol Int* 31:1409–1417. doi: 10.1007/s00296-011-1999-3
9. Ventafridda V, Saita L, Ripamonti C, De Conno F (1985) WHO guidelines for the use of analgesics in cancer pain. *Int J Tissue React* 7:93–6.
10. WHO (2013) WHO's cancer pain ladder for adults. <http://www.who.int/cancer/palliative/painladder/en/>. Accessed 30 Nov 2015
11. Kalso E, Edwards JE, Moore RA, McQuay HJ (2004) Opioids in chronic non-cancer pain: systematic review of efficacy and safety. *Pain* 112:372–80. doi: 10.1016/j.pain.2004.09.019
12. Rang H, Dale M, Ritter J, Flower R, Henderson G (2012) *Rang & Dale's Pharmacology*, 7th ed. Elsevier, London
13. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. *Annu Rev Pharmacol Toxicol* 38:97–120. doi: 10.1146/annurev.pharmtox.38.1.97
14. Silverstein F, Faich G, Goldstein J (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized. *Jama* 284:1247–1255.
15. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. *N Engl J Med* 343:1520–1528. doi: 11087881
16. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. *Lancet* 364:665–674. doi: 10.1016/S0140-6736(04)16893-1
17. Solomon SD, McMurray JJ V, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. *N Engl J Med* 352:1071–80. doi: 10.1056/NEJMoa050405
18. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanasa A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med* 352:1092–102. doi: 10.1056/NEJMoa050493
19. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors. *JAMA J Am Med Assoc* 286:954–959. doi: 10.1001/jama.286.8.954
20. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoelt A, Parlow JL, Boyce SW, Verburg KM (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac

- surgery. *N Engl J Med* 352:1081–91. doi: 10.1056/NEJMoa050330
21. Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RSJ, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC (2007) Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. *N Engl J Med* 357:360–9. doi: 10.1056/NEJMoa071841
 22. Cullen L, Kelly L, Connor SO, Fitzgerald DJ (1998) Selective cyclooxygenase-2 inhibition by nimesulide in man. *J Pharmacol Exp Ther* 287:578–82.
 23. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. *Proc Natl Acad Sci* 96:272–277. doi: 10.1073/pnas.96.1.272
 24. Zarraga IGE, Schwarz ER (2007) Coxibs and Heart Disease. What We Have Learned and What Else We Need to Know. *J Am Coll Cardiol* 49:1–14. doi: 10.1016/j.jacc.2006.10.003
 25. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P (2004) Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects. *Circulation* 109:1468–1471. doi: 10.1161/01.CIR.0000124715.27937.78
 26. Hecken A, Schwartz JI, Depré M, Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX2 versus COX1 in healthy volunteers. *J Clin Pharmacol* 40:1109–1120.
 27. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C (2006) Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. *BMJ* 332:1302–1308. doi: 10.1136/bmj.332.7553.1302
 28. McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. *JAMA* 296:1633–44. doi: 10.1001/jama.296.13.jrv60011
 29. Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez L a (2009) Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. *Circ Cardiovasc Qual Outcomes* 2:155–163. doi: 10.1161/CIRCOUTCOMES.108.805689
 30. Bhalra N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanasa A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet (London, England)* 382:769–79. doi: 10.1016/S0140-6736(13)60900-9
 31. European Medicines Agency (2005) Press Release: European Medicines Agency concludes action on COX-2 inhibitors. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/01/WC500059088.pdf. Accessed 7 Mar 2016
 32. European Medicines Agency (2006) Press Release: European Medicines Agency review concludes positive benefit-risk balance for nonselective NSAIDs. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/12/WC500017362.pdf. Accessed 7 Mar 2016
 33. Solomon DH, Rassen JA, Glynn RJ, Garneau K, Levin R, Lee J, Schneeweiss S (2010) The comparative safety of opioids for nonmalignant pain in older adults. *Arch Intern Med* 170:1979–86. doi: 10.1001/archinternmed.2010.450
 34. Christie MJ (2008) Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. *Br J Pharmacol* 154:384–396. doi: 10.1038/bjp.2008.100
 35. Trescot AM, Helm S, Hansen H, Benyamin R, Glaser SE, Adlaka R, Patel S, Manchikanti L

- (2008) Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. *Pain Physician* 11:S5–S62. doi: 18443640
36. Ballantyne JC, Mao J (2003) Opioid therapy for chronic pain. *N Engl J Med* 349:1943–53. doi: 10.1056/NEJMra025411
 37. Ngian G-S, Guymer EK, Littlejohn GO (2011) The use of opioids in fibromyalgia. *Int J Rheum Dis* 14:6–11. doi: 10.1111/j.1756-185X.2010.01567.x
 38. Goldenberg DL, Burckhardt C, Crofford L (2014) Management of Fibromyalgia Syndrome. 292:2388–2395.
 39. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta J-K (2007) Decreased Central -Opioid Receptor Availability in Fibromyalgia. *J Neurosci* 27:10000–10006. doi: 10.1523/JNEUROSCI.2849-07.2007
 40. Painter JT, Crofford LJ (2013) Chronic opioid use in fibromyalgia syndrome: a clinical review. *J Clin Rheumatol* 19:72–7. doi: 10.1097/RHU.0b013e3182863447
 41. Fitzcharles M, Ste-marie P a, Goldenberg DL, John X, Abbey S, Choinière M, Ko G, Moulin D, Panopalis P, Proulx J, Shir Y (2012) 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome. *Pain Res Manag* 18:1–52.
 42. Bernardy K, Klose P, Uçeyler N, Kopp I, Häuser W (2008) Methodological fundamentals for the development of the guideline. *Schmerz* 22:244–54. doi: 10.1007/s00482-008-0670-8
 43. Grape S, Schug SA, Lauer S, Schug BS (2010) Formulations of fentanyl for the management of pain. *Drugs* 70:57–72. doi: 10.2165/11531740-000000000-00000
 44. Pergolizzi J, Aloisi AM, Dahan A, Filitz J, Langford R, Likar R, Mercadante S, Morlion B, Raffa RB, Sabatowski R, Sacerdote P, Torres LM, Weinbroum AA (2010) Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile. *Pain Pract* 10:428–450. doi: 10.1111/j.1533-2500.2010.00378.x
 45. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso E a, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice ASC, Stacey BR, Treede R-D, Turk DC, Wallace MS (2007) Pharmacologic management of neuropathic pain: evidence-based recommendations. *Pain* 132:237–51. doi: 10.1016/j.pain.2007.08.033
 46. Campbell BJ, Rowbotham M, Davies PS, Jacob P, Benowitz NL (2002) Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. *J Pharm Sci* 91:1343–50. doi: 10.1002/jps.10133
 47. Derry S, Wiffen P, Moore R, Quinlan J (2014) Topical lidocaine for neuropathic pain in adults (Review). *Cochrane Database Syst. Rev.*
 48. Micó J a, Ardid D, Berrocoso E, Eschalier A (2006) Antidepressants and pain. *Trends Pharmacol Sci* 27:348–54. doi: 10.1016/j.tips.2006.05.004
 49. Arnold LM, Keck PEJ, Welge JA (2000) Antidepressant treatment of fibromyalgia. A meta-analysis and review. *Psychosomatics* 41:104–113.
 50. Häuser W, Walitt B, Fitzcharles M-A, Sommer C (2014) Review of pharmacological therapies in fibromyalgia syndrome. *Arthritis Res Ther* 16:201. doi: 10.1186/ar4441
 51. Watson CPN, Chipman ML, Monks RC (2006) Antidepressant analgesics: a systematic review and comparative study. In: McMahon S, Koltzenburg M (eds) *Wall Melzack's Textb. Pain.*, 5th ed. Elsevier, London, p 1280
 52. Taylor CP, Angelotti T, Fauman E (2007) Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta subunit as a target for antiepileptic drug discovery. *Epilepsy Res* 73:137–50. doi: 10.1016/j.eplepsyres.2006.09.008
 53. Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su T-Z, Bramwell S, Corradini L, England S, Winks J, Kinloch RA, Hendrich J, Dolphin AC, Webb T, Williams D (2006) Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. *Proc Natl Acad Sci U S A* 103:17537–42. doi: 10.1073/pnas.0409066103
 54. Crofford LJ, Mease PJ, Simpson SL, Young JP, Martin S a., Haig GM, Sharma U (2008)

- Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin. *Pain* 136:419–431. doi: 10.1016/j.pain.2008.02.027
55. Vargas-Schaffer G (2010) Is the WHO analgesic ladder still valid? Twenty-four years of experience. *Can Fam Physician* 56:514–7, e202–5.
 56. Pergolizzi BJ V, Raffa RB (2014) The WHO Pain Ladder: Do We Need Another Step? *Pract Pain Manag* 14:1–17.
 57. Watts RW, Silagy CA (1995) A meta-analysis on the efficacy of epidural corticosteroids in the treatment of sciatica. *Anaesth Intensive Care* 23:564–9.
 58. McQuay H, Moore R (1998) Epidural corticosteroids for sciatica. In: *An Evidence-Based Resour. Pain Reli.* Oxford University Press, Oxford, p 270
 59. Boswell M V, Colson JD, Sehgal N, Dunbar EE, Epter R (2007) A systematic review of therapeutic facet joint interventions in chronic spinal pain. *Pain Physician* 10:229–253.
 60. Staal JB, de Bie R, de Vet HC, Hildebrandt J, Nelemans P (2008) Injection therapy for subacute and chronic low-back pain. *Cochrane Database Syst Rev* CD001824. doi: 10.1002/14651858.CD001824.pub3
 61. Geurts JW, van Wijk RM, Stolker RJ, Groen GJ (2001) Efficacy of radiofrequency procedures for the treatment of spinal pain: a systematic review of randomized clinical trials. *Reg Anesth Pain Med* 26:394–400. doi: 10.1053/rapm.2001.23673
 62. Schofferman J, Kine G (2004) Effectiveness of repeated radiofrequency neurotomy for lumbar facet pain. *Spine (Phila Pa 1976)* 29:2471–3.
 63. Onofrio B, Yaksh T, Arnold P (1981) Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. *Mayo Clin Proc* 56:516–520.
 64. Levy R, Salzman D (1997) Implanted drug delivery systems for control of chronic pain. In: North R, Levy R (eds) *Neurosurg. Manag. Pain.* Springer, New York, NY, pp 302–324
 65. Prager J (2002) Neuraxial medication delivery: the development and maturity of a concept for treating chronic pain of spinal origin. *Spine (Phila Pa 1976)* 27:2593–2605.
 66. Raphael JH, Duarte R V, Southall JL, Nightingale P, Kitas GD (2013) Randomised, double-blind controlled trial by dose reduction of implanted intrathecal morphine delivery in chronic non-cancer pain. *BMJ Open* 3:e003061.
 67. Melzack R, Wall PD (1965) Pain Mechanisms: A New Theory. *Science (80-)* 150:971–979. doi: 10.1126/science.150.3699.971
 68. Linderoth B, Foreman RD (1999) Physiology of Spinal Cord Stimulation: Review and Update. *Neuromodulation* 2:150–164. doi: 10.1046/j.1525-1403.1999.00150.x
 69. NICE (2008) Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin. In: *NICE Technol. Apprais. Guid. [TA159].* <http://www.nice.org.uk/guidance/ta159/>. Accessed 26 Nov 2015
 70. Cameron T (2004) Safety and efficacy of spinal cord stimulation for the treatment of chronic pain: a 20-year literature review. *J Neurosurg* 100:254–67.
 71. Kumar K, Taylor RS, Jacques L, Eldabe S, Meglio M, Molet J, Thomson S, O’Callaghan J, Eisenberg E, Milbouw G, Buchser E, Fortini G, Richardson J, North RB (2008) The Effects of Spinal Cord Stimulation in Neuropathic Pain Are Sustained: A 24-month follow-up of the prospective randomized controlled multicenter trial of the effectiveness of spinal cord stimulation. *Neurosurgery* 63:762–770. doi: 10.1227/01.NEU.0000325731.46702.D9
 72. Sparkes E, Duarte R V, Mann S, Lawrence TR, Raphael JH (2015) Analysis of psychological characteristics impacting spinal cord stimulation treatment outcomes: a prospective assessment. *Pain Physician* 18:E369–E377.
 73. Linderoth B, Foreman RD (2006) Mechanisms of Spinal Cord Stimulation in Painful Syndromes: Role of Animal Models. *Pain Med* 7:S14–S26. doi: 10.1111/j.1526-4637.2006.00119.x
 74. Wu M, Linderoth B, Foreman RD (2008) Putative mechanisms behind effects of spinal cord stimulation on vascular diseases: a review of experimental studies. *Auton Neurosci* 138:9–23. doi:

- 10.1016/j.autneu.2007.11.001
75. Claeys LG, Horsch S (1996) Transcutaneous oxygen pressure as predictive parameter for ulcer healing in endstage vascular patients treated with spinal cord stimulation. *Int Angiol* 15:344–349.
 76. Amann W, Berg P, Gersbach P, Gamain J, Raphael JH, Ubbink DT (2003) Spinal cord stimulation in the treatment of non-reconstructable stable critical leg ischaemia: Results of the European Peripheral Vascular Disease Outcome Study (SCS-EPOS). *Eur J Vasc Endovasc Surg* 26:280–286. doi: 10.1053/ejvs.2002.1876
 77. Norrsell H, Eliasson T, Albertsson P, Augustinsson LE, Emanuelsson H, Eriksson P, Mannheimer C (1998) Effects of spinal cord stimulation on coronary blood flow velocity. *Coron Artery Dis* 9:273–278.
 78. Kingma JG, Linderoth B, Ardell JL, Armour JA, DeJongste MJ, Foreman RD (2001) Neuromodulation therapy does not influence blood flow distribution or left-ventricular dynamics during acute myocardial ischemia. *Auton Neurosci* 91:47–54. doi: 10.1016/S1566-0702(01)00285-5
 79. Hautvast RWM, Blanksma PK, Dejongste MJL, Pruijm J, Wall EE Van Der, Vaalburg W, Lie KI (1996) Effect of Spinal Cord Stimulation on Myocardial Blood Flow Assessed by Positron Emission Tomography in Patients With Refractory Angina Pectoris. *Am J Cardiol* 77:462–467.
 80. Börjesson M, Andrell P, Lundberg D, Mannheimer C (2008) Spinal cord stimulation in severe angina pectoris - A systematic review based on the Swedish Council on Technology assessment in health care report on long-standing pain. *Pain* 140:501–508. doi: 10.1016/j.pain.2008.10.016
 81. Taylor RS, De Vries J, Buchser E, Dejongste MJL (2009) Spinal cord stimulation in the treatment of refractory angina: systematic review and meta-analysis of randomised controlled trials. *BMC Cardiovasc Disord* 9:13. doi: 10.1186/1471-2261-9-13
 82. Eldabe S, Thomson S, Duarte R, Brookes M, DeBelder M, Raphael J, Davies E, Taylor R (2016) The Effectiveness and Cost-Effectiveness of Spinal Cord Stimulation for Refractory Angina (RASCAL Study): A Pilot Randomized Controlled Trial. *Neuromodulation* 19:60-70.
 83. Rasche D, Rinaldi PC, Young RF, Tronnier VM (2006) Deep brain stimulation for the treatment of various chronic pain syndromes. *Neurosurg Focus* 21:E8. doi: 10.3171/foc.2006.21.6.10
 84. Bittar RG, Kar-Purkayastha I, Owen SL, Bear RE, Green A, Wang S, Aziz TZ (2005) Deep brain stimulation for pain relief: A meta-analysis. *J Clin Neurosci* 12:515–519. doi: 10.1016/j.jocn.2004.10.005
 85. Boccard SGJ, Pereira EAC, Aziz TZ (2015) Deep brain stimulation for chronic pain. *J Clin Neurosci* 22:1537–1543. doi: 10.1016/j.jocn.2015.04.005
 86. NICE (2011) Deep brain stimulation for refractory chronic pain syndromes (excluding headache).
 87. Cruccu G, Aziz TZ, Garcia-Larrea L, Hansson P, Jensen TS, Lefaucheur J-P, Simpson B a, Taylor RS (2007) EFNS guidelines on neurostimulation therapy for neuropathic pain. *Eur J Neurol* 14:952–70. doi: 10.1111/j.1468-1331.2007.01916.x
 88. Boccard SGJ, Pereira EAC, Moir L, Aziz TZ, Green AL (2013) Long-term outcomes of deep brain stimulation for neuropathic pain. *Neurosurgery* 72:221–230. doi: 10.1227/NEU.0b013e31827b97d6
 89. Rosen AC, Ramkumar M, Nguyen T, Hoeft F (2009) Noninvasive transcranial brain stimulation and pain. *Curr Pain Headache Rep* 13:12–17.
 90. Marlow NM, Bonilha HS, Short EB (2013) Efficacy of transcranial direct current stimulation and repetitive transcranial magnetic stimulation for treating fibromyalgia syndrome: a systematic review. *Pain Pract* 13:131–145. doi: 10.1111/j.1533-2500.2012.00562.x
 91. Reinert A, Treede R, Bromm B (2000) The pain inhibiting pain effect: an electrophysiological study in humans. *Brain Res* 862:103–10.
 92. Wand-Tetley JI (1956) Historical methods of counter-irritation. *Ann Phys Med* 3:90–99.
 93. Carroll D, Ra M, Hj M, Fairman F, Tramèr M, Leijon G (2000) Transcutaneous electrical nerve stimulation (TENS) for chronic pain (Review). *Cochrane Libr*.
 94. Kane K, Taub A (1975) A history of local electrical analgesia. *Pain* 1:125–38.

95. Johnson MI (2014) *Transcutaneous Electrical Nerve Stimulation (TENS): Research to support clinical practice*. Oxford University Press, Oxford
96. Nash T, Williams J, Machin D (1990) TENS: does the type of stimulus really matter? *Pain Clin* 3:161–168.
97. McQuay H, Moore R, Eccleston C, Morley S, Williams AC (1997) Systematic review of outpatient services for chronic pain control. *Health Technol Assess (Rockv)* 1:138.
98. Raphael JH, Raheem TA, Southall JL, Bennett A, Ashford RL, Williams S (2011) Randomized double-blind sham-controlled crossover study of short-term effect of percutaneous electrical nerve stimulation in neuropathic pain. *Pain Med* 12:1515–22. doi: 10.1111/j.1526-4637.2011.01215.x
99. Turnbull A (1850) *Tincture of capsaicin as a remedy for chilblains and toothache*. Dublin Free Press 95–96.
100. Szallasi A, Blumberg PM (1999) Vanilloid (Capsaicin) receptors and mechanisms. *Pharmacol Rev* 51:159–212.
101. Anand P, Bley K (2011) Topical capsaicin for pain management: Therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8 patch. *Br J Anaesth* 107:490–502. doi: 10.1093/bja/aer260
102. Jones VM, Moore KA, Peterson DM (2011) Capsaicin 8% Topical Patch (Qutenza)—A Review of the Evidence. *J. Pain Palliat. Care Pharmacother*.
103. Maihofner C, Heskamp M-L (2013) Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. *Curr Med Res Opin* 29:673–83. doi: 10.1185/03007995.2013.792246
104. Health and Social Care Information Centre (2014) Prescription cost analysis - England 2013. HSCIC 677.
105. Oosterveld FG, Rasker JJ (1994) Treating arthritis with locally applied heat or cold. *Semin Arthritis Rheum* 24:82–90.
106. Brosseau L, Yonge K a, Robinson V, Marchand S, Judd M, Wells G, Tugwell P (2003) Thermotherapy for treatment of osteoarthritis. *Cochrane Database Syst Rev* CD004522. doi: 10.1016/S0031-9406(05)60490-7
107. Malanga G a, Nadler SF (1999) Nonoperative treatment of low back pain. *Mayo Clin Proc* 74:1135–1148. doi: 10.4065/74.11.1135
108. Lehmann JF, Warren CG, Scham SM (1974) Therapeutic heat and cold. *Clin Orthop Relat Res* 207–245.
109. Le Bars D, Dickenson AH, Besson JM (1979) Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. *Pain* 6:283–304.
110. Moont R, Pud D, Sprecher E, Sharvit G, Yarnitsky D (2010) “Pain inhibits pain” mechanisms: Is pain modulation simply due to distraction? *Pain* 150:113–120. doi: 10.1016/j.pain.2010.04.009
111. Melzack R (1999) From the gate to the neuromatrix. *Pain* 82:S121–S126.
112. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D (2006) Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. *Eur J Pain* 10:287–333.
113. Price C, Hoggart B, Olukoga O, Williams ACDC, Bottle A (2012) National Pain Audit Final Report 2010-2012.
114. Sabers S (2003) The role of physical therapy in chronic pain. In: Rice A, Warfield C, Justins D, Eccleston C (eds) *Clin. Pain Manag. Chronic Pain*. Arnold, London, pp 313–324
115. Hayden J, Van Tulder M, Malmivaara A, Koes B (2005) Exercise therapy for treatment of non-specific low back pain. *Cochrane Database Syst Rev* 83.
116. Engel J (2013) Evaluation and Pain Management. In: Pendleton H, Schultz-Krohn W (eds) *Pendretti’s Occup. Ther.*, 7th ed. Elsevier Mosby, MO, p 1328
117. Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. *Clin Ther* 23:1296–1310. doi: 10.1016/S0149-2918(01)80109-0

118. Turk DC, Monarch E (2002) Biopsychosocial Perspective on Chronic Pain. In: Turk D, Gatchel RJ (eds) *Psychol. Approaches to Pain Manag.*, 2nd ed. Guilford Press, New York, NY, p 590
119. Williams S (2013) *Pain Management Programmes 2013 National Directory of Services.*
120. Jeffery MM, Butler M, Stark A, Kane RL (2011) *Multidisciplinary Pain Programs for Chronic Noncancer Pain.* Agency for Healthcare Research and Quality (US), Rockville, MD
121. Loeser JD, Turk DC (2001) *Multidisciplinary Pain Management.* In: Loeser JD (ed) *Bonica's Manag. Pain*, 3rd ed. Lippincott, Williams & Wilkins, Philadelphia, PA, pp 2069–2079
122. British Pain Society (2013) *The British Pain Society Guidelines for Pain Management Programmes for adults.*
123. Beck A, Rush A, Shaw B, Emery G (1979) *Cognitive Therapy of Depression.* Guilford Press, New York, NY
124. Eccleston C (2001) Role of psychology in pain management. *Br J Anaesth* 87:144–152. doi: 10.1093/bja/87.1.144
125. Turk D, Meichenbaum D, Genest M (1983) *Pain and behavioral medicine: A cognitive-behavioral perspective.* Guilford Press, New York, NY
126. Bogaards MC, ter Kuile MM (1994) Treatment of recurrent tension headache: a meta-analytic review. *Clin J Pain* 10:174–90.
127. Morley S, Eccleston C, Williams A (1999) Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. *Pain* 80:1–13.
128. Hoffman B, Papas R, Chatkoff D, Kerns R (2007) Meta-analysis of psychological interventions for chronic low back pain. *Heal Psychol* 26:1–9. doi: 10.1037/0278-6133.26.1.1
129. Henschke N, Ostelo R, Van Tulder M, Vlaeyen J, Morley S, Assendelft W, Main C (2010) Behavioural treatment for chronic low-back pain (Review). *Cochrane Database Syst Rev* 1–124.
130. Williams ACDC, Eccleston C, Morley S (2012) Psychological therapies for the management of chronic pain (excluding headache) in adults (Review). *Cochrane Libr.*
131. Moore RK, Groves D, Bateson S, Barlow P, Hammond C, Leach AA, Chester MR (2005) Health related quality of life of patients with refractory angina before and one year after enrolment onto a refractory angina program. *Eur J Pain* 9:305–10. doi: 10.1016/j.ejpain.2004.07.013
132. Moore RKG, Groves DG, Bridson JD, Grayson AD, Wong H, Leach A, Lewin RJP, Chester MR (2007) A Brief Cognitive-Behavioral Intervention Reduces Hospital Admissions in Refractory Angina Patients. *J Pain Symptom Manage* 33:310–316. doi: <http://dx.doi.org/10.1016/j.jpainsymman.2006.10.009>
133. Hayes SC, Strosahl KD, Wilson KG (1999) *Acceptance and commitment therapy: An experiential approach to behavior change.* Guilford Press, New York, NY
134. Hayes S (2004) Acceptance and commitment therapy, relational frame theory, and the third wave of behavioral and cognitive therapies. *Behav Ther* 35:639–665. doi: 10.1016/S0005-7894(04)80013-3
135. Hayes S (2004) Acceptance and commitment therapy and the new behaviour therapies. In: Hayes SC, Follette V, Linehan M (eds) *Mindfulness Accept. Expand. Cogn. Tradit.* Guilford Press, New York, NY, pp 1–29
136. Hayes SC, Luoma JB, Bond FW, Masuda A, Lillis J (2006) Acceptance and commitment therapy: model, processes and outcomes. *Behav Res Ther* 44:1–25. doi: 10.1016/j.brat.2005.06.006
137. McCracken LM, Morley S (2014) The psychological flexibility model: A basis for integration and progress in psychological approaches to chronic pain management. *J Pain* 15:221–234. doi: 10.1016/j.jpain.2013.10.014
138. Sturgeon J (2014) Psychological therapies for the management of chronic pain. *Psychol Res Behav Manag* 7:115–124. doi: 10.2147/PRBM.S44762
139. Kabat-Zinn J (1994) *Wherever You Go, There You Are: Mindfulness Meditation in Everyday Life.* Hyperion, New York, NY
140. Veehof MM, Oskam M-J, Schreurs KMG, Bohlmeijer ET (2011) Acceptance-based interventions

- for the treatment of chronic pain: A systematic review and meta-analysis. *Pain* 152:533–542. doi: 10.1016/j.pain.2010.11.002
141. Hann KEJ, McCracken LM (2014) A systematic review of randomized controlled trials of Acceptance and Commitment Therapy for adults with chronic pain: Outcome domains, design quality, and efficacy. *J Context Behav Sci* 3:1–39. doi: 10.1016/j.jcbs.2014.10.001

Accepted for publication